Rani Therapeutics Reports the Results for RT-111 Capsules Containing CT-P43 (biosimilar, ustekinumab) in P-I Trial for the Treatment of Various Indications
Shots:
- The P-I clinical trial evaluates the safety & efficacy of RT-111 in delivering CT-P43 (biosimilar, ustekinumab) in patients with moderate to severe plaque psoriasis, active psoriatic arthritis & IBD
- As per the results, RT-111 delivered CT-P43 in a dose proportional manner with high bioavailability & depicted a higher Cmax & shorter Tmax vs ustekinumab delivered by SC injection
- RT-11 is a RaniPill capsule that contains CT-P43, a biosimilar of Ustekinumab, a human IgG1қ mAb that functions by binding with specificity to the p40 protein subunit used by both the IL-12 & IL-23 cytokines
Ref: Rani Therapeutics | Image: Rani Therapeutics
Related News:- Rani Therapeutics Initiates P-I Study of RT-111 (biosimilar, ustekinumab) for Autoimmune Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
